Skip to content
value.today

Cara Therapeutics Inc

Total raised
$5 M
1 round on record
Latest round
$5 M
Jul 2010
First round on record
Jul 2010
Today
Went public
See the company page

Cara Therapeutics Inc is listed today as Tvardi Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Cara Therapeutics Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2010$5 MNo. 1$2 to $10 million

Cara Therapeutics Inc: Raise no. 1, Jul 2010

Investors in this round

12 investors had bought by the notice of Jul 21, 2010: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Cara Therapeutics Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $15 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Series D Preferred Stock convertible into Common Stock
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Derek Chalmers · Executive Officer, Director
  • Frederique Menzaghi · Executive Officer
  • Josef Schoell · Executive Officer
  • Christopher M. Moller · Director
  • Dean Slagel · Director
  • Ed Hurwitz · Director
  • Jeffrey M. Jonas · Director
  • Martin Vogelbaum · Director
  • Stephen Reeders · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Derek Chalmers, President & CEO. Newest notice filed Jul 21, 2010. Read the notice at the SEC.

equity, optionsSEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Cara Therapeutics Inc chose not to state its revenue in its newest notice of a funding round (Jul 2010).

    SEC Form D · Jul 2010

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2010

Products and services#

No products or services of Cara Therapeutics Inc are on record.

Investors#

9 named in official filings. Open an investor to see everything it has backed.

Investors in Cara Therapeutics Inc
InvestorKindAmountRoundRoleSource
Alta Biopharma Management III LLCFund or asset managernot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Alta Biopharma Partners III Gmbh & Co Beteiligungs KGFund or asset managernot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Alta Biopharma Partners III LPFund or asset managernot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Alta Embarcadero Biopharma Partners III LLCFund or asset managernot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Derek T. ChalmersPersonnot statednot statedHeld Series A and D preferred stock, director (Form 3, 2014)SEC Form 3
Michael E. LewisPersonnot statednot statedHeld Series A and D preferred stock (Form 3, 2014)SEC Form 3
Rho Capital Partners LLCFund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
RHO Ventures VI LPVenture capitalnot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
RMV VI, L.L.C.Othernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2014)SEC Form 3

Largest shareholders today

Institutions holding Tvardi Therapeutics, Inc. shares, as of Sep 30, 2026.

As of Sep 30, 2026

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Cara Therapeutics Inc
NameRoleNamed in
Derek ChalmersExecutive officerJul 2010
Frederique MenzaghiExecutive officerJul 2010
Josef SchoellExecutive officerJul 2010
Christopher M. MollerDirectorJul 2010
Dean SlagelDirectorJul 2010
Derek ChalmersDirectorJul 2010
Ed HurwitzDirectorJul 2010
Jeffrey M. JonasDirectorJul 2010
Martin VogelbaumDirectorJul 2010
Stephen ReedersDirectorJul 2010

Went public since 2014. Its SEC number is that of a company listed on a stock exchange.